PAUL L BERNS

CIK 1202769 · See Remarks · last filed 2026-06-24

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$26.93M

Companies

13

Total Filings

100

Lifetime Open-Market Net

$121.97M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KARD Director 15,062,741 $20.00M 2 2026-06-24
LYEL 10%+ Owner 910,317 $13.93 $12.68M $112.50M 1 2026-03-09
NMRA See Remarks 7,528,282 $1.62 $12.23M -$57.9K 7 2026-02-19
Metsera, Inc. (MTSR) Delisted Director 0 $70.50 $0 $14.22M 3 2025-11-13
Unity Biotechnology, Inc. (UBX) Delisted Director 326 $0.20 $65 $0 7 2024-06-21
EQRx, Inc. (EQRXW) Delisted Director 0 $0.05 $0 $0 4 2023-11-09
JAZZ Director 8,290 $244.26 $2.02M -$3.76M 23 2021-08-09
VYNE Therapeutics Inc. (MNLO) Delisted Director $0 2 2019-08-08
Anacor Pharmaceuticals, Inc. (ANAC) Delisted President and CEO 0 $10.19 $0 -$16.52M 14 2016-06-24
XENOPORT INC (XNPT) Delisted Director 15,000 -$525.2K 10 2016-05-19
Cellectar Biosciences, Inc. (CLRB.Z) Delisted Director 117,371 $248.8K 1 2016-04-21
Cellectar Biosciences, Inc. (CLRB.W) Delisted Director $0 2 2015-06-10
ALLOS THERAPEUTICS INC (ALTH) Delisted Chief Executive Officer 0 -$4.14M 22 2012-09-05

Recent Filings · Page 2 of 10

100 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-02-18 NMRA Notice (144) −13,871 -$23.5K EDGAR
2025-02-18 NMRA Mixed $0 EDGAR
2025-02-03 Metsera, Inc. (MTSR) Delisted Mixed +8,313,680 $14.22M EDGAR
2024-12-27 NMRA Gift (G) −399,291 $0 EDGAR
2024-06-21 Unity Biotechnology, Inc. (UBX) Delisted Grant (A) $0 EDGAR
2024-02-16 NMRA Grant (A) +171,250 $0 EDGAR
2023-11-09 EQRx, Inc. (EQRXW) Delisted Disp (D) −627,000 $0 EDGAR
2023-06-26 Unity Biotechnology, Inc. (UBX) Delisted Grant (A) $0 EDGAR
2023-01-04 EQRx, Inc. (EQRXW) Delisted Grant (A) $0 EDGAR
2022-10-04 EQRx, Inc. (EQRXW) Delisted Grant (A) $0 EDGAR
Showing 1120 of 100
Page 2 of 10
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.